New Platform Enhances CAR T-Cell Therapy for Relapsed Leukemia

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of leukemia, but relapse remains a significant challenge. Now, a novel biomimetic platform developed by researchers at the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences offers a promising solution to improve outcomes for patients with relapsed and refractory leukemia without requiring genetic modification of CAR T-cells.

The Challenge of Relapse in CAR T-Cell Therapy

CAR T-cell therapy involves engineering a patient’s T-cells to recognize and eliminate leukemia cells. However, over 50% of patients experience relapse after treatment. A primary driver of this relapse is the reduction or loss of the targeted antigen on leukemia cells, rendering CAR T-cells ineffective. [1] Previous approaches to overcome this limitation have focused on complex and time-consuming genetic engineering of CAR structures.

A Biomimetic Approach: FACE Technology

The IPE researchers have developed a biomimetic platform that enhances CAR T-cell therapy without altering the CAR T-cells themselves. This strategy centers around a molecular “bridge” called a ferritin aggregation cell engager (FACE). FACE is created by inducing the self-assembly of ferritin, a natural protein involved in iron transport, and is designed to reinforce the interaction between CAR T-cells and leukemia cells.

The researchers discovered that CD71, a protein involved in iron transport, is highly expressed on both leukemia cells and CAR T-cells. FACE binds to CD71 on the surface of CAR T-cells and, after infusion, also attaches to CD71 on leukemia cells, effectively linking the two cell types and strengthening their interaction. [2]

Enhanced Efficacy in Preclinical Models

In preclinical studies using mouse models of relapsed and refractory leukemia, FACE-CAR T-cells demonstrated significant improvements in efficacy. In models with normal antigen expression, FACE-CAR T-cells achieved the same therapeutic effect as conventional CAR T-cells but with a reduced cell dose, potentially minimizing the risk of cytokine release syndrome. [4]

Importantly, FACE-CAR T-cells remained effective even when leukemia antigen levels dropped to as low as 10% of normal levels—a scenario where conventional CAR T-cells are largely ineffective. In these challenging conditions, FACE-CAR T-cells achieved 100% survival in preclinical models.

Targeted Drug Delivery with FACED

The researchers further refined the platform by developing a drug-loaded FACE (FACED), utilizing ferritin’s cage-like structure to deliver therapeutic agents directly to leukemia cells. FACED-CAR T-cells effectively treated models with high leukemia burden and low antigen expression, and even eliminated antigen-negative leukemia cells, a major cause of relapse.

Scalability and Clinical Potential

The FACE platform is composed of an endogenous protein and FDA-approved polymer derivatives, making it simple and scalable to produce. It can be seamlessly integrated into existing CAR T-cell manufacturing workflows as a culture supplement, co-incubated with CAR T-cells prior to infusion, without requiring additional genetic engineering. [2]

“Our FACE platform is composed of an endogenous protein and FDA-approved polymer derivatives and can be prepared through a simple and scalable process. Importantly, it can be seamlessly integrated into existing CAR T cell manufacturing workflows as a culture supplement that is co-incubated with CAR T cells prior to infusion, without any additional genetic engineering of CARs,” explained Prof. WEI Wei from IPE.

AI-Assisted Predictive Framework

The researchers systematically evaluated FACE across diverse patient-derived leukemia samples and clinically relevant models, demonstrating its broad applicability. They also established an efficacy database and developed an AI-assisted predictive framework to accurately forecast FACE-mediated enhancement. [2]

Peer reviewers at Cell described the findings as “highly relevant to the CAR T field” and a “promising translational approach” to improving responsiveness against hematologic malignancies, emphasizing the potential to counteract the heterogeneity of leukemia antigens.

Looking Ahead

This study presents a promising new strategy to enhance CAR T-cell therapy for relapsed and refractory leukemia. The FACE platform offers a practical and scalable approach to improve outcomes by strengthening cell engagement and enabling targeted drug delivery. Further clinical trials will be necessary to validate these findings and bring this innovative technology to patients.